SCHEDULE 13G/A: Cadian Capital Management Discloses 4.2% Stake in Guardant Health
Beneficial Ownership Report (Schedule 13G Amendment)
Cadian Capital Management, LP, along with its general partner and managing member Eric Bannasch, has disclosed a beneficial ownership of 4.2% in Guardant Health, Inc. as of December 31, 2024.
Summary
- Cadian Capital Management, LP, Cadian Capital Management GP, LLC, and Eric Bannasch (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
- The filing reports beneficial ownership of 5,221,565 shares of Common Stock in Guardant Health, Inc.
- This ownership represents approximately 4.2% of Guardant Health's outstanding Common Stock.
- The percentage is based on 123,554,612 shares of Common Stock outstanding as of November 1, 2024, as disclosed in Guardant Health's Form 10-Q filed on November 6, 2024.
- The Reporting Persons exercise shared voting and shared dispositive power over all 5,221,565 shares.
- The securities are held directly by Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP, which are advisory clients of Cadian Capital Management, LP.
Sentiment
Score: 6
Explanation: The sentiment is mildly positive as it indicates a significant institutional investor has taken or maintained a stake in the company, suggesting confidence. However, a Schedule 13G is primarily a factual disclosure of ownership and does not provide operational or financial performance insights.
Positives
- The disclosure of a significant stake by an institutional investor like Cadian Capital Management can be viewed as a vote of confidence in Guardant Health's future prospects.
- The investment is stated to be acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Guardant Health, Inc. or the Reporting Persons regarding the issuer's future performance.
Industry Context
This filing reflects an institutional investment firm's position in a publicly traded company within the healthcare technology or diagnostics sector. Such disclosures are routine and provide transparency into significant ownership stakes, which can sometimes signal investor confidence or strategic interest in the company's market segment.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder, which can influence market perception and potentially share price.
- Management: Awareness of a large shareholder's position, though the filing states the stake is not for control purposes.
Key Dates
| Date | Description |
|---|---|
| 2024-11-01 | Date as of which 123,554,612 shares of Common Stock were outstanding, as disclosed in Guardant Health's Form 10-Q. |
| 2024-11-06 | Date Guardant Health's Form 10-Q was filed with the SEC. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G (beneficial ownership snapshot date). |
| 2025-02-13 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
Guardant Health, Cadian Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, GRNT
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.